Last reviewed · How we verify
NCT05572996
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
trial testing Inhaled Treprostinil in Pulmonary Hypertension. Available.
Quick facts
| Lead sponsor | Ferrer Internacional S.A. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Inhaled Treprostinil — full drug profile →
Conditions studied
- Pulmonary Hypertension — all drugs for Pulmonary Hypertension →
- Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
- Combined Pulmonary Fibrosis and Emphysema — all drugs for Combined Pulmonary Fibrosis and Emphysema →
Sponsor
Ferrer Internacional S.A. — full company profile →
Who can join
18 and older, any sex, with Pulmonary Hypertension or Interstitial Lung Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05572996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Inhaled Treprostinil
Trials testing the same drug.
- NCT05255991 — Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · Phase 3 · completed
- NCT04708782 — Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · Phase 3 · completed
- NCT03814317 — Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension · Phase 2 · completed
- NCT02630316 — Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE · Phase 2, PHASE3 · completed
- NCT02633293 — An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE · Phase 2, PHASE3 · terminated
Other recruiting trials for Pulmonary Hypertension
Currently open trials in the same condition.
- NCT07179380 — Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension · Phase 3 · recruiting
- NCT07073820 — A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have P · Phase 2 · recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07187206 — Safety and Efficacy of FETO in CDH Phase III · Phase 3 · recruiting
- NCT07206173 — Londrina Activities of Daily Living Protocol in Pulmonary Hypertension · recruiting
Other Ferrer Internacional S.A. trials
Trials by the same sponsor.
- NCT06499363 — Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Sa · recruiting
- NCT05866926 — Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis · Phase 3 · terminated
- NCT05178810 — Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Scler · Phase 3 · completed
- NCT04065529 — Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in t · Phase 3 · completed
- NCT02525991 — Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05572996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ferrer Internacional S.A.
- Last refreshed: 10 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05572996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing